{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:03:25Z","timestamp":1792641805312,"version":"4.5.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00614","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T04:54:55Z","timestamp":1594097695000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":82,"title":["A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders"],"prefix":"10.3389","volume":"11","author":[{"given":"Sagrario","family":"Manzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ag\u00fcera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Olazar\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer's disease facts and figures","volume":"12","author":"Alzheimer's","year":"2016","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"key":"B2","article-title":"World Alzheimer Report 2015","author":"Prince","year":"2015","journal-title":"The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1017\/S1041610217001211","article-title":"Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study","volume":"29","author":"Olazar\u00e1n","year":"2017","journal-title":"Int Psychogeriatr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.20344\/amp.6025","article-title":"The epidemiology of dementia and Alzheimer disease in Portugal: estimations of prevalence and treatment-costs","volume":"28","author":"Santana","year":"2015","journal-title":"Acta Med Port."},{"key":"B5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science."},{"key":"B6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.jalz.2018.06.3040","article-title":"The antimicrobial protection hypothesis of Alzheimer's disease","volume":"14","author":"Moir","year":"2018","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1172\/JCI25100","article-title":"The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease","volume":"115","author":"Gandy","year":"2005","journal-title":"J Clin Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble A\u03b2 peptide with Tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol Aging."},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1017\/S1748232107000171","article-title":"Targeting amyloid with tramiprosate in patients with mild-to-moderate Alzheimer disease","volume":"3","author":"Aisen","year":"2008","journal-title":"Prog Neurother Neuropsychopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer's disease: mechanisms and therapeutic strategies","volume":"15","author":"Gao","year":"2018","journal-title":"Curr Alzheimer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nri1843","article-title":"Immunology and immunotherapy of Alzheimer's disease","volume":"6","author":"Weiner","year":"2006","journal-title":"Nat Rev Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-018-08279-3","article-title":"Neuropathological correlates and genetic architecture of microglial activation in elderly human brain","volume":"10","author":"Felsky","year":"2019","journal-title":"Nat Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1212\/WNL.53.2.321","article-title":"APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study","volume":"53","author":"Breitner","year":"1999","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.neurobiolaging.2003.12.023","article-title":"ApoE genotype accounts for the vast majority of AD risk and AD pathology","volume":"25","author":"Raber","year":"2004","journal-title":"Neurobiol Aging."},{"key":"B17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00406-015-0663-4","article-title":"Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer's disease","volume":"266","author":"De Luca","year":"2016","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain."},{"key":"B19","doi-asserted-by":"publisher","first-page":"a006312","DOI":"10.1101\/cshperspect.a006312","article-title":"Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.med.47.1.387","article-title":"Apolipoprotein E alleles as risk factors in Alzheimer's disease","volume":"47","author":"Roses","year":"1996","journal-title":"Annu. Rev. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature11087","article-title":"Apolipoprotein E controls cerebrovascular integrity via cyclophilin A","volume":"485","author":"Bell","year":"2012","journal-title":"Nature."},{"key":"B22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement. J Alzheimers Assoc."},{"key":"B24","first-page":"13","article-title":"Biomarcadores de l\u00edquido cefalorraqu\u00eddeo en la Enfermedad de Alzheimer","volume":"232","author":"Llad\u00f3","year":"2018","journal-title":"Inf. Psiqui\u00e1tr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40478-018-0535-z","article-title":"Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias","volume":"6","author":"Wren","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e00776","DOI":"10.1002\/brb3.776","article-title":"Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline","volume":"7","author":"Eliassen","year":"2017","journal-title":"Brain Behav."},{"key":"B27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14283\/jpad.2016.115","article-title":"Clinical benefits of tramiprosate in Alzheimer's disease are associated with higher number of APOE4 alleles: the APOE4 gene-dose effect","volume":"3","author":"Abushakra","year":"2016","journal-title":"J Prev Alzheimers Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","article-title":"Elucidating the A\u03b242 anti-aggregation mechanism of action of tramiprosate in Alzheimer's disease: integrating molecular analytical methods, pharmacokinetic and clinical Data","volume":"31","author":"Kocis","year":"2017","journal-title":"CNS Drugs."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis","author":"Tolar","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fnagi.2018.00285","article-title":"Anti-inflammatory effects of homotaurine in patients with amnestic mild cognitive impairment","volume":"10","author":"Boss\u00f9","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3233\/JAD-150484","article-title":"Homotaurine effects on hippocampal volume loss and episodic memory in amnestic mild cognitive impairment","volume":"50","author":"Spalletta","year":"2016","journal-title":"J Alzheimers Dis."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000102531","article-title":"Involvement of both gaba-dependent and - independent pathways in tramiprosate neuroprotective effects against amyloid- \u03b2eta toxicity","volume":"4","author":"Azzi","year":"2007","journal-title":"Neurodegener Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/j.jalz.2007.04.153","article-title":"P-190: GABA-dependent pathways in the neuroprotective effect of tramiprosate against amyloid-toxicity","volume":"3","author":"Galarneau","year":"2007","journal-title":"Alzheimers Dement J Alzheimers Assoc."},{"key":"B36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer's disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","article-title":"Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain","volume":"32","author":"Hey","year":"2018","journal-title":"CNS Drugs."},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1750-1326-2-17","article-title":"Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau","volume":"2","author":"Santa-Maria","year":"2007","journal-title":"Mol Neurodegener."},{"key":"B39","article-title":"Tramiprosate Prevents Amyloid Beta-induced Inhibition of Long-term Potentiation in Rat Hippocampal Slices","author":"Krzywkowski","year":"2007","journal-title":"8th Int. Conf. AD\/PD."},{"key":"B40","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1016\/j.jalz.2007.04.155","article-title":"P-192: tramiprosate decreases amyloid-beta; induced ERK1\/2 activity in primary rat neurons by a GABA-independent pathway","volume":"3","author":"Greenberg","year":"2007","journal-title":"Alzheimer's Dement. J. Alzheimer's Assoc."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","article-title":"A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease","volume":"67","author":"Aisen","year":"2006","journal-title":"Neurology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer's disease multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2017.26","article-title":"Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer's disease suggest disease modification potential","volume":"4","author":"Abushakra","year":"2017","journal-title":"J Prev Alzheimers Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"J Nutr Heal Aging."},{"key":"B45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12603-009-0047-4","article-title":"Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMEDTM (tramiprosate) experience","volume":"13","author":"Saumier","year":"2009","journal-title":"J Nutr Heal Aging."},{"key":"B46","doi-asserted-by":"publisher","first-page":"136","DOI":"10.14283\/jpad.2017.24","article-title":"Clinical effects of oral tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer's disease suggest disease modification","volume":"4","author":"Sabbagh","year":"2017","journal-title":"J Prev Alzheimers Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J Intern Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1017\/S1041610297004870","article-title":"Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type","volume":"9","author":"Morris","year":"1997","journal-title":"Int Psychogeriatr."},{"key":"B50","first-page":"15","article-title":"Effect of homotaurine in patients with cognitive impairment: results from an Italian observational retrospective study","volume":"66","author":"Martorana","year":"2018","journal-title":"J Gerontol Geriatr."},{"key":"B51","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fnagi.2014.00254","article-title":"Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals","volume":"6","author":"Martorana","year":"2014","journal-title":"Front Aging Neurosci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s10072-015-2201-6","article-title":"Homotaurine in Parkinson's disease","volume":"36","author":"Ricciardi","year":"2015","journal-title":"Neurol. Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.wad.0000213845.28624.f4","article-title":"A phase 2 study of tramiprosate for cerebral amyloid angiopathy","volume":"20","author":"Greenberg","year":"2006","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"B54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0197-4580(92)90027-U","article-title":"Identification of normal and pathological aging in prospectively studied nondemented elderly humans","volume":"13","author":"Dickson","year":"1992","journal-title":"Neurobiol Aging."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.neurobiolaging.2009.04.002","article-title":"Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease","volume":"30","author":"Price","year":"2009","journal-title":"Neurobiol Aging."},{"key":"B56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1385\/jmn:17:2:101","article-title":"Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease","volume":"17","author":"Morris","year":"2001","journal-title":"J Mol Neurosci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B58","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3275\/8585","article-title":"The potential protective effect of trampirosate (homotaurine) against Alzheimer's disease: a review","volume":"24","author":"Caltagirone","year":"2012","journal-title":"Aging Clin Exp Res."},{"key":"B59","first-page":"82","article-title":"Future strategies of management of Alzheimer's Disease","volume":"22","author":"Tsolaki","year":"2019","journal-title":"Hell J Nucl Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3233\/JAD-2003-5206","article-title":"Apolipoprotein E \u03b54 in an autopsy series of various dementing disorders","volume":"5","author":"Nielsen","year":"2003","journal-title":"J Alzheimers Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaneurol.2015.0606","article-title":"Clinical features of Alzheimer disease with and without lewy bodies","volume":"72","author":"Chung","year":"2015","journal-title":"JAMA Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?","volume":"134","author":"Compta","year":"2011","journal-title":"Brain."},{"key":"B63","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.pharmthera.2016.11.001","article-title":"Intensive LDL-cholesterol lowering therapy and neurocognitive function","volume":"170","author":"Banach","year":"2017","journal-title":"Pharmacol Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0304-3940(96)12373-9","article-title":"Apolipoprotein E polymorphism in patients with different neurodegenerative disorders","volume":"205","author":"Helisalmi","year":"1996","journal-title":"Neurosci Lett."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e0202044","DOI":"10.1371\/journal.pone.0202044","article-title":"Relative survival in patients with dementia with Lewy bodies and Parkinson's disease dementia","volume":"13","author":"Larsson","year":"2018","journal-title":"PLoS ONE."},{"key":"B66","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4103\/0366-6999.226069","article-title":"Hypertension-induced cerebral small vessel disease leading to cognitive impairment","volume":"131","author":"Liu","year":"2018","journal-title":"Chin Med J."},{"key":"B67","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.44.7.1330","article-title":"The apolipoprotein? 4 allele in Parkinson's disease with and without dementia","volume":"44","author":"Marder","year":"1994","journal-title":"Neurology."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.2174\/1871527313666140917121132","article-title":"Cholinergic system dysfunction and neurodegenerative diseases: cause or effect?","volume":"13","author":"Tata","year":"2014","journal-title":"CNS Neurol Disord Drug Targets."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1093\/brain\/aws207","article-title":"Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease","volume":"135","author":"Rochester","year":"2012","journal-title":"Brain."},{"key":"B70","doi-asserted-by":"publisher","first-page":"101752","DOI":"10.1016\/j.nicl.2019.101752","article-title":"Aberrant resting-state oscillatory brain activity in Parkinson's disease patients with visual hallucinations: an MEG source-space study","volume":"22","author":"Dauwan","year":"2019","journal-title":"Neuroimage Clin."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00702-017-1775-y","article-title":"Cortical afferent inhibition abnormalities reveal cholinergic dysfunction in Parkinson's disease: a reappraisal","volume":"124","author":"Nardone","year":"2017","journal-title":"J Neural Transm."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00702-015-1427-z","article-title":"Central cholinergic dysfunction could be associated with oropharyngeal dysphagia in early Parkinson's disease","volume":"122","author":"Lee","year":"2015","journal-title":"J Neural Transm."},{"key":"B73","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","article-title":"Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis","volume":"86","author":"Pagano","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.clinph.2017.03.011","article-title":"Olfactory dysfunction in early Parkinson's disease is associated with short latency afferent inhibition reflecting central cholinergic dysfunction","volume":"128","author":"Oh","year":"2017","journal-title":"Clin Neurophysiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jns.2017.03.049","article-title":"Impaired cholinergic transmission in patients with Parkinson's disease and olfactory dysfunction","volume":"377","author":"Versace","year":"2017","journal-title":"J Neurol Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.neurobiolaging.2005.10.004","article-title":"Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia","volume":"27","author":"Rom\u00e1n","year":"2006","journal-title":"Neurobiol Aging."},{"key":"B77","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1089\/neu.2017.5102","article-title":"Post-injury administration of galantamine reduces traumatic brain injury pathology and improves outcome","volume":"35","author":"Zhao","year":"2018","journal-title":"J Neurotrauma."},{"key":"B78","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3233\/JHD-160200","article-title":"Targeting the cholinergic system to develop a novel therapy for Huntington's disease","volume":"5","author":"D'Souza","year":"2016","journal-title":"J Huntingtons Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","article-title":"Primary age-related tauopathy (PART): a common pathology associated with human aging","volume":"128","author":"Crary","year":"2014","journal-title":"Acta Neuropathol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain."},{"key":"B81","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment combinations for Alzheimer's disease: current and future pharmacotherapy options","volume":"67","author":"Cummings","year":"2019","journal-title":"J Alzheimers Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T04:55:00Z","timestamp":1594097700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":81,"alternative-id":["10.3389\/fneur.2020.00614"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00614","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"article-number":"614"}}